Sickle cell disease is a single-gene disorder that affects hemoglobin, the oxygen-carrying molecule in red blood cells. A single mutation causes hemoglobin molecules to polymerize under certain conditions, deforming red cells into rigid, crescent shapes that lodge in small blood vessels. The consequences are cascading: vaso-occlusion triggers episodes of excruciating pain, chronic hemolytic anemia, inflammation, and progressive damage to organs including the kidneys, lungs, brain, and spleen. The disease is among the costliest chronic conditions in medicine, measured in both direct health care expenditure and lost human potential, and it disproportionately affects people of African, Mediterranean, Middle Eastern, and South Asian ancestry. Yet for all its molecular simplicity—one gene, one known mutation—the disease behaves with bewildering variability. Some patients endure frequent crises and early organ failure while others, carrying the same genotype, live comparatively well for decades. The reason for this divergence has remained one of the field’s most stubborn mysteries.

The Mount Sinai team, led by principal investigator Sarah McCuskee, MD, Assistant Professor of Emergency Medicine and of Global Health and Health Systems Design, believes the answer may lie substantially outside the genome—in the “exposome,” the cumulative measure of every environmental exposure an individual encounters from moment to moment across a lifetime. “We have heard time and time again from our patients: their lives impact their disease, and vice versa,” Dr. McCuskee said in announcing the award. “But until now, how daily life impacts sickle cell disease hasn’t been studied very much. We are excited to partner with people living with sickle cell disease to understand this better, while applying rigorous scientific methods to make sure our conclusions are impactful.” Her framing captures the project’s central ambition: to treat patient experience not as anecdote but as a valid signal that can be rigorously quantified, measured, and validated.

The biological logic behind the hypothesis is grounded in what preliminary work has already hinted at. Neighborhood and personal exposures are known to activate inflammatory pathways, alter vascular tone, and shift metabolic states—all processes directly implicated in sickle cell pathogenesis. Chronic psychosocial stress elevates cortisol and sympathetic nervous system activity, which can promote vasoconstriction and heighten the likelihood of vaso-occlusive events. Elevated ambient temperature is suspected of influencing blood viscosity and dehydration status, both critical variables in a disease where red cells sickle more readily when blood flow slows or plasma volume falls. Airborne particulate matter, particularly fine particles smaller than 2.5 micrometers, known as PM2.5, penetrates deep into the lungs and drives systemic inflammation through oxidative stress, an especially concerning mechanism for patients whose vasculature is already prone to inflammatory damage. Poor access to nutritious food may compromise the antioxidant defenses and hydration status that help keep sickling episodes at bay. Substandard housing—with inadequate heating, cooling, ventilation, or pest exposure—compounds all of these risks simultaneously.

The new study is among the first prospective investigations of exposures in sickle cell disease ever undertaken, and its methodology reflects the sophistication that such a claim demands. The researchers will pursue two complementary strategies. The first links blood samples previously donated by people with sickle cell disease for research to geospatial data on the exposures those individuals experience, drawing on advanced satellite-based models. These models can estimate ambient concentrations of fine particulate matter, neighborhood-level temperatures, and other environmental variables at fine resolution, allowing investigators to connect each participant’s residential history with molecular readouts of their disease state. The second strategy moves into real time: participants will carry portable air-quality sensors that directly measure the particles they breathe, and they will report on diet and stress levels as they occur. These moment-to-moment exposure data will then be linked to measurements of the body’s energy metabolism and inflammatory markers, giving researchers a dynamic picture of how a specific exposure on a specific day translates into molecular changes in the blood.

This pairing of satellite modeling and personal sensing is methodologically significant. Satellite data offers population-scale coverage and historical depth, but it estimates exposure at the ambient level and can miss what individuals actually encounter indoors, in transit, or in microenvironments like subway platforms and workplaces. Portable sensors capture the true inhaled dose but are limited in duration and cohort size. By triangulating the two approaches and anchoring both to biochemical endpoints—energy metabolism and inflammation—the study can distinguish between exposures that merely correlate with disease activity and those that plausibly drive it. If, for example, a spike in personally measured PM2.5 is followed within days by a rise in inflammatory cytokines and markers of hemolysis, the causal chain becomes far harder to dismiss. That kind of evidence, replicated across participants and seasons, is what regulatory policy and clinical guidance ultimately require.

The collaborative architecture of the project is equally deliberate. The research will be conducted in partnership with the Human Immune Monitoring Center at Mount Sinai, which provides deep immunophenotyping capability; the Institute for Exposomic Research at the Icahn School of Medicine, one of the first institutions in the world organized specifically around exposomic science; and the Center for Sickle Cell Disease, which anchors the clinical and community dimensions of the work. Exposomics—the systematic study of non-genetic drivers of health—has gained momentum in cancer, cardiovascular disease, and neurology, but its application to a monogenic disease like sickle cell is comparatively novel and potentially transformative, because it addresses the variability that the gene itself cannot explain.

Community partnership is not an afterthought in this design but a stated structural principle. When the study concludes, the researchers intend to share results widely, including through publicly available maps of neighborhood exposures co-developed with the New York City sickle cell community. That commitment matters for a disease whose patients have historically faced well-documented barriers in health care—under-treatment of pain, delayed emergency care, and skepticism about the severity of their symptoms. By giving the community access to the same exposure data that researchers use, the project aims to convert an academic finding into an advocacy tool, one that residents, clinicians, and policymakers can use to argue for cooler housing, cleaner air, and better food environments in the neighborhoods where sickle cell patients live.

The translational endpoint is clinical. Dr. McCuskee and her colleagues plan to develop tools based on their findings that will help clinicians counsel patients concretely—not in vague exhortations to “stay healthy,” but with specific, evidence-based guidance about which environmental conditions appear to elevate risk for a given individual, and what mitigations may help. Beyond sickle cell disease, the investigators hope the methods themselves—linking personal sensing, geospatial modeling, and molecular biomarkers—could form a template for investigating other chronic and genetic illnesses in which outcomes vary inexplicably from patient to patient, including cystic fibrosis, certain autoimmune conditions, and cardiovascular disease.

The grant will be distributed over five years, a duration long enough to capture seasonal variation in temperature, air quality, and stress exposures, and to observe whether exposure-driven molecular changes translate into clinical events such as pain crises, emergency department visits, or hospitalizations. If the study delivers on its promise, it could mark a turning point in how medicine understands a disease long defined by its genetics. The mutation in the hemoglobin gene has been known since the middle of the twentieth century; the environmental and social conditions that determine how severely that mutation expresses itself have, by comparison, barely been examined. Mount Sinai’s new program sets out to close that gap, grounded in the conviction that where people live is not background noise to their biology but part of it—and that understanding the two together may finally explain why one gene can produce so many different lives.

The collaboration between Mount Sinai and OpenAI ensures stringent protections are embedded within the use of ChatGPT Edu, including full compliance with the Health Insurance Portability and Accountability Act (HIPAA) and comprehensive safeguards for personal health information and other sensitive data. This agreement reflects a careful balance between technological advancement and ethical responsibility, aiming not only to expand educational capabilities but also to safeguard the privacy and integrity of the medical community’s data infrastructure.

ChatGPT Edu operates as a private, secure platform tailored to meet the exacting standards of medical education and research. Unlike general consumer AI applications, this specialized environment is designed to support a wide range of academic activities—from enhancing clinical reasoning and understanding complex patient cases to facilitating sophisticated data analysis and research coding—all while maintaining strict controls against misuse or inadvertent disclosure of protected information.

Mount Sinai’s decision to harness AI tools like ChatGPT Edu comes amid a broader institutional push to embed advanced computational methods and machine learning across its health system. Drawing upon the extensive data amassed within one of New York City’s largest health networks, students have immediate access to a rich repository of clinical and research information. Combining this data with AI’s analytical capabilities equips future physicians and scientists with unrivaled resources to interrogate medical questions, develop innovative hypotheses, and contribute meaningfully to translational medicine.

David C. Thomas, MD, MHPE, Dean for Medical Education at the Icahn School of Medicine, emphasizes the school’s deliberate and ethical approach to AI integration, noting the importance of fostering critical engagement with generative AI rather than blind adoption. The initiative is framed as an educational enhancement that underlines equity, academic integrity, and the cultivation of clinical judgment. According to Dr. Thomas, the AI platform is a powerful supplement that helps students develop the nuanced decision-making skills essential in a healthcare landscape increasingly influenced by intelligent technologies.

Integral to this rollout is the concept that AI assists, rather than replaces, human expertise. Training programs emphasize that ChatGPT Edu is a cognitive aid—much like a digital study partner—offering tools that help sharpen logic, refine diagnostic thinking, and streamline research efforts. Its role in supporting students’ learning objectives includes assisting with technical tasks such as programming, infrastructure configuration, and troubleshooting, enabling learners to focus on scientific inquiry and patient-centered care.

Faculty members are also actively exploring ChatGPT Edu’s potential to transform curriculum development and scholarly activities. By providing dynamic assistance in content creation—such as generating interactive educational materials and supporting data-driven research—this AI tool stands to accelerate innovation in pedagogical practices, fostering an adaptive and responsive educational ecosystem that can meet evolving learner needs.

Leah Belsky, Vice President and General Manager of Education at OpenAI, highlights the critical nature of familiarizing students across disciplines with AI technologies before entering a labor market permeated by machine learning tools. In the context of medical education specifically, responsible AI use is paramount, ensuring that emerging clinicians and researchers are equipped not only with technical proficiency but also with an ethical framework that respects both patient privacy and the limits of AI’s role in clinical decision-making.

The initiative’s oversight is provided by a dedicated Steering Committee on Teaching, Learning, and Discoveries, supported by a Research and Technologies Team alongside the Gustave L. and Janet W. Levy Library. This governance structure ensures ongoing evaluation and refinement of AI integration, focused on optimizing student experiences and maximizing curricular alignment. Early phases target a seamless introduction for medical and graduate students, with plans to expand AI access across broader cohorts within the Mount Sinai Health System.

Icahn School of Medicine leadership underscores that the introduction of AI tools complements but does not supplant clinical judgment. Anne and Joel Ehrenkranz Dean Dennis S. Charney, MD, stresses that AI serves to augment learners’ capacity for critical thinking, confidence, and problem-solving skills. Importantly, the enduring value of human intuition and patient-provider relationships remains central to the school’s educational mission, anchoring technological advancement within a humanistic practice of medicine.

This strategic AI adoption aligns with Mount Sinai’s series of landmark initiatives that hallmark its role as a pioneer in health technology innovation, including the establishment of a new dedicated AI building, the creation of the Center for Artificial Intelligence in Children’s Health, and the launch of the AI Small Molecule Drug Discovery Center. Together, these efforts portray a comprehensive institutional vision where artificial intelligence serves as a transformative force in shaping the future of medical research, education, and patient care.

By integrating ChatGPT Edu with rigorous data privacy frameworks and embedding it into an evidence-based medical curriculum, the Icahn School of Medicine is charting a responsible path forward—one that acknowledges both the immense potential and the ethical complexities of artificial intelligence in medicine. This initiative not only advances student learning but also lays the groundwork for a healthcare workforce equipped to harness AI’s power safely and effectively in improving patient outcomes.

With this innovative deployment, Mount Sinai sets a precedent for medical schools worldwide, demonstrating how technology and tradition can coalesce to produce a new paradigm in medical education—one where cutting-edge AI tools empower students without compromising core values of humanism, privacy, and responsibility. As AI continues to evolve and permeate healthcare, the lessons learned here will resonate across academic and clinical domains, informing policy, pedagogy, and practice in years to come.

Subject of Research: Medical education innovation and AI integration in healthcare training

Article Title: Icahn School of Medicine at Mount Sinai Pioneers Secure AI Integration with ChatGPT Edu for Medical Students

News Publication Date: May 5, 2025

Web References:

• https://www.mountsinai.org/about/newsroom/2024/mount-sinai-opens-the-hamilton-and-amabel-james-center-for-artificial-intelligence-and-human-health-to-transform-health-care-by-spearheading-the-ai-revolution
• https://www.mountsinai.org/about/newsroom/2025/mount-sinai-launches-center-for-artificial-intelligence-in-childrens-health-to-advance-ai-driven-outcomes-in-children
• https://www.mountsinai.org/about/newsroom/2025/mount-sinai-launches-ai-small-molecule-drug-discovery-center

Keywords: Medical Education, Artificial Intelligence, ChatGPT Edu, AI in Healthcare, Medical Research, Data Privacy, HIPAA Compliance, Clinical Reasoning, AI Ethics, Translational Medicine

Dr. Nadkarni’s appointment is a culmination of a series of progressive initiatives undertaken by Mount Sinai to implement artificial intelligence within healthcare. With the recent unveiling of a state-of-the-art AI facility, the institution aims to propel innovation and collaborative research in translational medicine. This facility will serve as a hub for cutting-edge projects that integrate AI technology into various aspects of patient care, education, and research.

AI’s integration into medicine is not merely about adopting new technology; it requires a cultural shift within healthcare systems to prioritize data-driven decision-making. Dr. Nadkarni’s goal is to ensure that AI methodologies are adopted in a way that not only improves clinical outcomes but also addresses concerns about bias in technology, their transparency, and ethical considerations. By working closely with existing clinicians and researchers across all departments at Mount Sinai, he will spearhead efforts aimed at developing AI tools that are effective, equitable, and beneficial for all patients.

One of the significant advancements on the horizon involves a new AI tool specifically designed for students at the Icahn School of Medicine. This initiative is expected to revolutionize medical education by integrating advanced AI resources directly into the curriculum, thus equipping the next generation of healthcare professionals with the skills necessary to leverage AI technologies in their practice. Additionally, this integration will provide students with hands-on experience in using AI for research and patient care, serving as a critical aspect of modern medical training.

Beyond education, Mount Sinai has also made substantial investments in enhancing its computational and data ecosystems. This includes the establishment of the largest supercomputing cluster at any academic medical center globally. This computational power is vital for conducting large-scale analyses and developing sophisticated AI algorithms that can lead to new insights and better patient management practices.

Dr. Nadkarni’s leadership is underscored by a strong collaborative ethos. He will work closely with Lisa S. Stump, the Chief Digital Information Officer and Dean for Information Technology at the Icahn School of Medicine. This partnership aims to unite data and technological platforms across the Mount Sinai Health System, focusing on facilitating quicker cures for diseases, enhancing patient outcomes, and streamlining operational efficiency. Their collaborative efforts signify a holistic approach to integrating AI effectively within the healthcare framework.

Mount Sinai’s commitment to AI extends beyond mere research; it signifies a paradigm shift in how healthcare is delivered. The institution fosters a culture that emphasizes safe and equitable AI adoption, positioning itself as a model for progressive and AI-enabled learning health systems. This ethos is echoed in statements from institutional leaders who express their enthusiasm for Dr. Nadkarni’s vision and the transformative potential of AI within clinical contexts.

As an advocate for responsible AI implementation, Dr. Nadkarni emphasizes the importance of conducting research that is not only innovative but also free from inherent biases. His extensive background in AI applications in healthcare includes pioneering work that addresses bias in algorithmic designs and ensures that AI tools are developed with equity in mind. This focus is crucial in a field where the implications of biased data can significantly affect patient care and health outcomes.

Dr. Nadkarni’s remarkable portfolio includes numerous patents for AI applications in medicine, showcasing his active role in bridging the gap between AI and clinical practice. He is notably recognized for co-inventing the first FDA-approved AI bioprognostic tool for assessing kidney disease, a milestone achievement that underscores the practical impact AI can have on improving diagnostic accuracy and patient stratification.

Moreover, being the Co-Director of The Charles Bronfman Institute for Personalized Medicine and Chief of the Division of Data-Driven and Digital Medicine at Mount Sinai, Dr. Nadkarni’s focus lies in integrating AI methodologies into precise patient care frameworks. His research encompasses various critical areas, including the implementation of predictive AI technologies across diverse medical conditions, highlighting the transformative potential of AI in improving clinical outcomes.

Given Dr. Nadkarni’s extensive contributions to national and international discussions on leveraging AI in healthcare, his appointment marks a pivotal moment for Mount Sinai. The institution is poised to lead the next wave of AI integration into medicine, firmly situating itself as a key player in global health innovation. Dr. Nadkarni’s innovative mindset and collaborative spirit are expected to drive vital advancements in healthcare delivery and scientific inquiry.

Recognizing the urgency of adopting AI responsibly, Dr. Nadkarni’s overarching vision is to ensure that the AI solutions developed are aligned with ethical standards and aimed at enhancing patient care while mitigating potential risks. His leadership embodies a comprehensive approach to technology integration that prioritizes patient welfare and systemic improvement, resonating deeply within the healthcare community.

As Mount Sinai continues to unfold its ambitious AI endeavors, the broader implications of Dr. Nadkarni’s appointment underscore a transformative journey that extends well beyond the institution itself. By setting new benchmarks for the integration of artificial intelligence in healthcare, Mount Sinai aims to amplify the collective impact of scientific advancements on global health outcomes.

Subject of Research: Artificial Intelligence in Healthcare
Article Title: Girish N. Nadkarni Appointed as Chair of Windreich Department of Artificial Intelligence and Human Health, Pioneering AI in Medicine
News Publication Date: January 30, 2025
Web References: Mount Sinai’s AI Department
References: Mount Sinai Health System
Image Credits: Credit: Mount Sinai Health System

Keywords: Artificial Intelligence, Healthcare Innovation, Biomedical Engineering, Clinical Applications of AI, Medical Education, Health Outcomes, Data-Driven Medicine, Ethical AI Implementation, AI and Bias in Healthcare.